These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3276445)

  • 1. Future prospects for vaccine adjuvants.
    Warren HS; Chedid LA
    Crit Rev Immunol; 1988; 8(2):83-101. PubMed ID: 3276445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in vaccine adjuvants.
    Singh M; O'Hagan D
    Nat Biotechnol; 1999 Nov; 17(11):1075-81. PubMed ID: 10545912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvants in perspective.
    Vogel FR
    Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
    Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
    Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.
    Pearse MJ; Drane D
    Vaccine; 2004 Jun; 22(19):2391-5. PubMed ID: 15193400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of CpG DNA as a mucosal vaccine adjuvant.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jump-starting the immune system: prime-boosting comes of age.
    Woodland DL
    Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine adjuvants: scientific challenges and strategic initiatives.
    Harandi AM; Davies G; Olesen OF
    Expert Rev Vaccines; 2009 Mar; 8(3):293-8. PubMed ID: 19249971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
    Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvants for malaria vaccines.
    Coler RN; Carter D; Friede M; Reed SG
    Parasite Immunol; 2009 Sep; 31(9):520-8. PubMed ID: 19691556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction and direction of immune responses by vaccine adjuvants.
    Schijns VE
    Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunology of vaccine adjuvants.
    Ribeiro CM; Schijns VE
    Methods Mol Biol; 2010; 626():1-14. PubMed ID: 20099117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvants for porcine reproductive and respiratory syndrome virus vaccines.
    Charerntantanakul W
    Vet Immunol Immunopathol; 2009 May; 129(1-2):1-13. PubMed ID: 19157569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
    Koprowski H
    Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.